Search

Share:

The Internet site that you are about to view is an online educational resource intended
for medical professionals based in the United Kingdom. The site contains up-to-date
information on The Binding Site’s products, and may therefore contain information on
medical devices and other products or uses of those products that are not approved or
cleared in other countries or regions.
This site is not intended to promote off label use of any of The Binding Site’s
products. To obtain appropriate product information for your country of residence,
please contact your local distributor.

In around 5-7% of patients, AL amyloidosis is associated with IgM paraprotein [1131][1132][1133][1134] and in over half of cases the condition is secondary to non-Hodgkin lymphoma [1135]. Although IgM AL amyloidosis shares a number of characteristics with non-IgM AL amyloidosis [1136][1137], it represents a distinct clinical entity [1137]. IgM AL amyloidosis is characterised by a higher incidence of lymph node and neuropathic involvement, and less severe cardiac dysfunction when compared to non-IgM AL amyloidosis [1132][1135]. Generally, IgM AL amyloidosis patients have lower levels of iFLCs than non-IgM patients (median 63 mg/L vs. 182 mg/L), which are more commonly of the κ type (42% vs. 23%) [1131][1132][1135].